Advanced search

Online first
Conference report / Report
Published online: 2025-01-17

open access

View PDF Download PDF file
Page views 131
Article views/downloads 63
Get Citation

Connect on Social Media

Connect on Social Media

Advances in oncology after the 2024 European Society for Medical Oncology (ESMO) congress

Dawid Sigorski123, Małgorzata Osmola34, Bartosz Spławski5, Sylwia Tabor36, Mirosława Püsküllüoğlu7, Renata Pacholczak-Madej8910, Edyta Hunia-Prejsnar311, Michał Gola212, Michał Wilk313, Agnieszka Markiewicz14, Joanna Kiszka311

Abstract

The European Society of Medical Oncology (ESMO) Congress is the most important and clinically relevant oncological conference in Europe. It provides a forum to share the latest advances in cancer research, diagnostics, and treatment. In this review, we present the most significant new data on cancer treatment, which may change future oncological and patient outcomes.

Keywords: ESMOhead and neck cancerslung cancerbreast cancergastric cancercolorectal cancerpancreatic cancerkidney cancerprostate cancerbladder cancermelanoma

Article available in PDF format

View PDF Download PDF file

References

  1. Tao Y, Auperin A, Sun X, et al. 854MO Avelumab-cetuximab-radiotherapy (RT) versus standards of care in patients with locally advanced squamous cell carcinoma of head and neck (LA-SCCHN): Final analysis of randomized phase III GORTEC 2017-01 REACH trial. Ann Oncol. 2024; 35: S616.
    CrossRef
  2. Kristensen CA, Metcalf R, Braña I, et al. LBA35 Primary results from TACTI-003: A randomized phase IIb trial comparing eftilagimod alpha (soluble LAG-3) plus pembrolizumab versus pembrolizumab alone in first-line recurrent or metastatic head and neck squamous cell carcinoma with CPS ≥1. Ann Oncol. 2024; 35: S1227.
    CrossRef
  3. Kinoshita I, Kano S, Honma Y, et al. 849O Phase II study of trastuzumab deruxtecan in patients with HER2-positive recurrent/metastatic salivary gland cancer: Results from the MYTHOS trial. Ann Oncol. 2024; 35: S613–S614.
    CrossRef
  4. Machiels JP, René Leemans C, Golusinski W, et al. EHNS Executive Board. Electronic address: secretariat@ehns.org, ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org, ESTRO Executive Board. Electronic address: info@estro.org. Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020; 31(11): 1462–1475.
    CrossRefPubMed
  5. Yeoh CC, Dabab N, Rigby E, et al. Androgen receptor in salivary gland carcinoma: A review of an old marker as a possible new target. J Oral Pathol Med. 2018; 47(7): 691–695.
    CrossRefPubMed
  6. Licitra L, Locati LD, Digue L, et al. LBA36 A randomised phase II study to evaluate the efficacy and safety of androgen deprivation therapy (ADT) vs chemotherapy (CT) in patients with recurrent and/or metastatic, androgen receptor (AR) expressing, salivary gland cancers. Ann Oncol. 2024; 35: S1227–S1228.
    CrossRef
  7. Elmusrati A, Wang J, Wang CY. Tumor microenvironment and immune evasion in head and neck squamous cell carcinoma. Int J Oral Sci. 2021; 13(1): 24.
    CrossRefPubMed
  8. Chong WQ, Low JL, Sooi K, et al. 848MO Phase II open-label randomized study of pembrolizumab with or without bevacizumab in platinum-resistant recurrent/metastatic nasopharyngeal carcinoma (R/M NPC). Ann Oncol. 2024; 35: S614.
    CrossRef
  9. Pulla MP, Awad M, Cascone T, et al. LBA50 Perioperative nivolumab (NIVO) v placebo (PBO) in patients (pts) with resectable NSCLC: Clinical update from the phase III CheckMate 77T study. Ann Oncol. 2024; 35: S1239–S1240.
    CrossRef
  10. Heymach JV, Harpole D, Reck M, et al. AEGEAN Investigators. Perioperative Durvalumab for Resectable Non-Small-Cell Lung Cancer. N Engl J Med. 2023; 389(18): 1672–1684.
    CrossRefPubMed
  11. Reck M, Gale D, Zhu Z, et al. LBA49 Associations of ctDNA clearance (CL) during neoadjuvant Tx with pathological response and event-free survival (EFS) in pts with resectable NSCLC (R-NSCLC): Expanded analyses from AEGEAN. Ann Oncol. 2024; 35: S1239.
    CrossRef
  12. Wu YL, Dziadziuszko R, Ahn JS, et al. ALINA Investigators. Alectinib in Resected -Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2024; 390(14): 1265–1276.
    CrossRefPubMed
  13. Solomon BJ, Wu YL, Dziadziuszko R, et al. 1206MO ALINA: Exploratory biomarker analyses in patients (pts) with resected ALK+ non-small cell lung cancer (NSCLC) treated with adjuvant alectinib vs chemotherapy (chemo). Ann Oncol. 2024; 35: S775.
    CrossRef
  14. Lu S, Kato T, Dong X, et al. LAURA Trial Investigators. Osimertinib after Chemoradiotherapy in Stage III -Mutated NSCLC. N Engl J Med. 2024; 391(7): 585–597.
    CrossRefPubMed
  15. Lu S, Ahn MJ, Baisamut TR, et al. 1241MO Osimertinib (osi) after definitive chemoradiotherapy (CRT) in unresectable (UR) stg III EGFRm NSCLC: Analyses of CNS and distant progression from the phase III LAURA study. Ann Oncol. 2024; 35: S794–S795.
    CrossRef
  16. Drilon AE, Lin JJ, Johnson ML, et al. 1253O Phase I/II ALKOVE-1 study of NVL-655 in ALK-positive (ALK+) solid tumours. Ann Oncol. 2024; 35: S802–S803.
    CrossRef
  17. Zhou C, Tang KJ, Cho BC, et al. PAPILLON Investigators. Amivantamab plus Chemotherapy in NSCLC with Exon 20 Insertions. N Engl J Med. 2023; 389(22): 2039–2051.
    CrossRefPubMed
  18. Park K, Haura EB, Leighl NB, et al. Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study. J Clin Oncol. 2021; 39(30): 3391–3402.
    CrossRefPubMed
  19. Passaro A, Yu HA, Nguyen D, et al. 1254MO Safety and anti-tumour activity of zipalertinib in NSCLC patients (pts) with EGFR exon 20 insertion (ex20ins) mutations who received prior amivantamab. Ann Oncol. 2024; 35: S803–S804.
    CrossRef
  20. Riely GJ, Ahn MJ, Clarke J, et al. LBA56 Updated efficacy and safety from the phase II PHAROS study of encorafenib plus binimetinib in patients with BRAF V600E-mutant metastatic NSCLC (mNSCLC). Ann Oncol. 2024; 35: S1246–S1247.
    CrossRef
  21. Hortobagyi G, Stroyakovsky D, Yardley D, et al. Abstract GS03-03: Ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) as adjuvant treatment in patients with HR+/HER2− early breast cancer: final invasive disease–free survival (iDFS) analysis from the NATALEE trial. Cancer Res. 2024; 84(9_Supplement): GS03-03-GS03–03.
    CrossRef
  22. Harbeck N, Ciruelos E, Jerusalem G, et al. DESTINY-Breast12 study group, DESTINY-Breast12 study group. Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial. Nat Med. 2024; 30(12): 3717–3727.
    CrossRefPubMed
  23. Modi S, Saura C, Yamashita T, et al. DESTINY-Breast01 Investigators. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer. N Engl J Med. 2020; 382(7): 610–621.
    CrossRefPubMed
  24. Lin N, Ciruelos EM, Jerusalem G, et al. LBA18 Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2+ advanced/metastatic breast cancer (mBC) with or without brain metastases (BM): DESTINYBreast-12 primary results. Ann Oncol. 2024; 35: S1211–S1212.
    CrossRef
  25. Schmid P, Cortés J, Dent RA, et al. LBA4 Neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo for high-risk early-stage TNBC: Overall survival results from the phase III KEYNOTE-522 study. Ann Oncol. 2024; 35: S1204–S1205.
    CrossRef
  26. Mittendorf EA, Zhang H, Barrios CH, et al. Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial. Lancet. 2020; 396(10257): 1090–1100.
    CrossRefPubMed
  27. Rivera S, Ghodssighassemabadi R, Brion T, et al. 231O Locoregional hypo vs normofractionated RT in early breast cancer: 5 years results of the HypoG-01 phase III UNICANCER trial. Ann Oncol. 2024; 35: S309.
    CrossRef
  28. Leong T, Smithers BM, Michael M, et al. LBA58 A randomized phase III trial of perioperative chemotherapy (periop CT) with or without preoperative chemoradiotherapy (preop CRT) for resectable gastric cancer (AGITG TOPGEAR): Final results from an intergroup trial of AGITG, TROG, EORTC and CCTG. Ann Oncol. 2024; 35: S1249.
    CrossRef
  29. Liu DS, Hall K, Wong D, et al. 1402MO An international study evaluating pathological response to guide adjuvant FLOT chemotherapy in gastroesophageal cancer. Ann Oncol. 2024; 35: S879.
    CrossRef
  30. Janjigian YY, Laarhoven Hv, Rha SY, et al. 1401O Trastuzumab deruxtecan (T-DXd) monotherapy and combinations in patients (pts) with advanced/metastatic HER2-positive (HER2+) esophageal, gastric or gastroesophageal junction adenocarcinoma (GEJA): DESTINY-Gastric03 (DG-03). Ann Oncol. 2024; 35: S878.
    CrossRef
  31. Janjigian YY, Kawazoe A, Bai Y, et al. 1400O Final overall survival for the phase III, KEYNOTE-811 study of pembrolizumab plus trastuzumab and chemotherapy for HER2+ advanced, unresectable or metastatic G/GEJ adenocarcinoma. Ann Oncol. 2024; 35: S877–S878.
    CrossRef
  32. Peng Z, Wang J, Zhang Y, et al. LBA60 Phase III study of SHR-1701 versus placebo in combination with chemo as first-line (1L) therapy for HER2-negative gastric/gastroesophageal junction adenocarcinoma (G/GEJA). Ann Oncol. 2024; 35: S1250.
    CrossRef
  33. Lorenzen S, Goetze TO, Thuss-Patience PC, et al. LBA59 Modified FOLFOX plus/minus nivolumab and ipilimumab vs FLOT plus nivolumab in patients with previously untreated advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction: Final results of the IKF-AIO-Moonlight trial. Ann Oncol. 2024; 35: S1249–S1250.
    CrossRef
  34. Llovet J, Finn RS, Ren Z, et al. LBA3 Transarterial chemoembolization (TACE) with or without lenvatinib (len) + pembrolizumab (pembro) for intermediate-stage hepatocellular carcinoma (HCC): Phase III LEAP-012 study. Ann Oncol. 2024; 35: S1229.
    CrossRef
  35. Lambert A, Bouche O, Ayav A, et al. LBA62 Preoperative modified FOLFIRINOX (mFOLFIRINOX) with or without chemoradiation (CRT) in borderline resectable pancreatic cancer (BRPC): Results from the randomized phase II trial PANDAS/PRODIGE 44. Ann Oncol. 2024; 35: S1252.
    CrossRef
  36. Vogel A, Oh DY, He AR, et al. 55P Subsequent anticancer therapy (SAT) analysis from 3-year follow-up of the phase III TOPAZ-1 study of durvalumab plus gemcitabine and cisplatin in biliary tract cancer (BTC). Ann Oncol. 2024; 35: S233–S234.
    CrossRef
  37. Cervantes B, André T, Cohen R. Deficient mismatch repair/microsatellite unstable colorectal cancer: therapeutic advances and questions. Ther Adv Med Oncol. 2024; 16: 17588359231170473.
    CrossRefPubMed
  38. Rao S, Guren MG, Khan K, et al. ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Anal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021; 32(9): 1087–1100.
    CrossRefPubMed
  39. Chalabi M, Dungen Lv, Verschoor YL, et al. LBA24 Neoadjuvant immunotherapy in locally advanced MMR-deficient colon cancer: 3-year disease-free survival from NICHE-2. Ann Oncol. 2024; 35: S1217–S1218.
    CrossRef
  40. Gooyer Pde, Verschoor YL, Dungen Lv, et al. 503O Neoadjuvant nivolumab (nivo) plus relatlimab (rela) in MMR-deficient colon cancer: Results of the NICHE-3 study. Ann Oncol. 2024; 35: S428–S429.
    CrossRef
  41. Rao S, Samalin-Scalzi E, Evesque L, et al. LBA2 POD1UM-303/InterAACT 2: Phase III study of retifanlimab with carboplatin-paclitaxel (c-p) in patients (Pts) with inoperable locally recurrent or metastatic squamous cell carcinoma of the anal canal (SCAC) not previously treated with systemic chemotherapy (Chemo). Ann Oncol. 2024; 35: S1217.
    CrossRef
  42. Kataoka K, Mori K, Nakamura Y, et al. 558P Survival benefit of adjuvant chemotherapy based on molecular residual disease detection in resected colorectal liver metastases: Subgroup analysis from CIRCULATE-Japan GALAXY. Ann Oncol. 2024; 35: S459–S460.
    CrossRef
  43. Wysocki PJ, Chłosta P, Antoniewicz A, et al. Zalecenia postępowania diagnostyczno-terapeutycznego w raku pęcherza moczowego. Onkol Prakt Klin Edu. 2022; 8(4): 229–291.
  44. Sigorski D, Osmola M, Wilk M. Advances in genitourinary cancer treatment after the 2023 ESMO congress. Oncol Clin Pract. 2024.
    CrossRef
  45. Powles TB, Heijden MSv, Galsky MD, et al. LBA5 A randomized phase III trial of neoadjuvant durvalumab plus chemotherapy followed by radical cystectomy and adjuvant durvalumab in muscle-invasive bladder cancer (NIAGARA). Ann Oncol. 2024; 35: S1271.
    CrossRef
  46. Necchi A, Guerrero-Ramos F, Crispen PL, et al. LBA84 TAR-200 plus cetrelimab (CET) or CET alone as neoadjuvant therapy in patients (pts) with muscle-invasive bladder cancer (MIBC) who are ineligible for or refuse neoadjuvant cisplatin-based chemotherapy (NAC): Interim analysis of SunRISe-4 (SR-4). Ann Oncol. 2024; 35: S1271–S1272.
    CrossRef
  47. Jensen JB, Birkenkamp-Demtröder K, Nordentoft I, et al. 1960O Identification of bladder cancer patients that could benefit from early post-cystectomy immunotherapy based on serial circulating tumour DNA (ctDNA) testing: Preliminary results from the TOMBOLA trial. Ann Oncol. 2024; 35: S1133.
    CrossRef
  48. Powles TB, Valderrama BP, Gupta S, et al. LBA6 EV-302/KEYNOTE-A39: Open-label, randomized phase III study of enfortumab vedotin in combination with pembrolizumab (EV+P) vs chemotherapy (Chemo) in previously untreated locally advanced metastatic urothelial carcinoma (la/mUC). Ann Oncol. 2023; 34: S1340.
    CrossRef
  49. Powles TB, Heijden MSv, Gupta S, et al. 1966MO EV-302: Exploratory analysis of nectin-4 expression and response to 1L enfortumab vedotin (EV) + pembrolizumab (P) in previously untreated locally advanced or metastatic urothelial cancer (la/mUC). Ann Oncol. 2024; 35: S1137–S1138.
    CrossRef
  50. Koshkin VS, Barthelemy P, Gravis G, et al. 1965MO Phase II study of futibatinib plus pembrolizumab in patients (pts) with advanced/metastatic urothelial carcinoma (mUC): Final analysis of efficacy and safety. Ann Oncol. 2024; 35: S1136–S1137.
    CrossRef
  51. Zhao J, Du F, Shen G, et al. The role of hypoxia-inducible factor-2 in digestive system cancers. Cell Death Dis. 2015; 6(1): e1600.
    CrossRefPubMed
  52. Rini BI, Rodriguez CS, Albiges L, et al. LBA74 Final analysis of the phase III LITESPARK-005 study of belzutifan versus everolimus in participants (pts) with previously treated advanced clear cell renal cell carcinoma (ccRCC). Ann Oncol. 2024; 35: S1262–S1263.
    CrossRef
  53. Choueiri TK, Motzer RJ, Beckermann K, et al. LBA73 Tivozanib–nivolumab vs tivozanib monotherapy in patients with renal cell carcinoma (RCC) following 1 or 2 prior therapies including an immune checkpoint inhibitor (ICI): Results of the phase III TiNivo-2 study. Ann Oncol. 2024; 35: S1261–S1262.
    CrossRef
  54. Kaptein FHJ, van der Hulle T, Braken SJE, et al. Prevalence, Treatment, and Prognosis of Tumor Thrombi in Renal Cell Carcinoma. JACC CardioOncol. 2022; 4(4): 522–531.
    CrossRefPubMed
  55. Toren P, Abouassaly R, Timilshina N, et al. Results of a national population-based study of outcomes of surgery for renal tumors associated with inferior vena cava thrombus. Urology. 2013; 82(3): 572–577.
    CrossRefPubMed
  56. Gu L, Cheng P, Liang Q, et al. 1701P NEOTAX: A phase II trial of neoadjuvant toripalimab plus axitinib for clear cell renal cell carcinoma with inferior vena cava tumor thrombus. Ann Oncol. 2024; 35: S1019.
    CrossRef
  57. Powles T, Burotto M, Escudier B, et al. Nivolumab plus cabozantinib versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended follow-up from the phase III randomised CheckMate 9ER trial. ESMO Open. 2024; 9(5): 102994.
    CrossRefPubMed
  58. Braun DA, Wang Y, Yu A, et al. 1694MO Novel serum glycoproteomic biomarkers predict response to nivolumab plus cabozantinib (NIVO+CABO) versus sunitinib (SUN) in advanced RCC (aRCC): Analysis from CheckMate 9ER. Ann Oncol. 2024; 35: S1012–S1013.
    CrossRef
  59. Bergmann L, Ahrens M, Albiges L, et al. LBA75 Prospective randomised phase-II trial of ipilimumab/nivolumab versus standard of care in non-clear cell renal cell cancer: Results of the SUNNIFORECAST trial. Ann Oncol. 2024; 35: S1263.
    CrossRef
  60. Parker C, Nilsson S, Heinrich D, et al. ALSYMPCA Investigators. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013; 369(3): 213–223.
    CrossRefPubMed
  61. Smith M, Parker C, Saad F, et al. Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019; 20(3): 408–419.
    CrossRefPubMed
  62. Gillessen S, Choudhury A, Saad F, et al. LBA1 A randomized multicenter open label phase III trial comparing enzalutamide vs a combination of Radium-223 (Ra223) and enzalutamide in asymptomatic or mildly symptomatic patients with bone metastatic castration-resistant prostate cancer (mCRPC): First results of EORTC-GUCG 1333/PEACE-3. Ann Oncol. 2024; 35: S1254.
    CrossRef
  63. Sartor O, Jiang DM, Smoragiewicz M, et al. LBA65 Efficacy of 177Lu-PNT2002 in PSMA-positive mCRPC following progression on an androgen-receptor pathway inhibitor (ARPI) (SPLASH). Ann Oncol. 2024; 35: S1254–S1255.
    CrossRef
  64. Agarwal N, Azad AA, Galceran JC, et al. LBA67 Cabozantinib (C) plus atezolizumab (A) versus 2nd novel hormonal therapy (NHT) in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC): Final overall survival (OS) results of the phase III, randomized, CONTACT-02 study. Ann Oncol. 2024; 35: S1256–S1257.
    CrossRef
  65. Lucas MW, Menzies AM, Lopez-Yurda M, et al. LBA42 Distant metastasis-free survival of neoadjuvant nivolumab plus ipilimumab versus adjuvant nivolumab in resectable, macroscopic stage III melanoma: The NADINA trial. Ann Oncol. 2024; 35: S1233–S1234.
    CrossRef
  66. Long GV, Robert C, Hill AG, et al. 1082O KEYMAKER-U02 substudy 02C: Neoadjuvant pembrolizumab (pembro) and investigational agents followed by adjuvant pembro for stage IIIB-D melanoma. Ann Oncol. 2024; 35: S712–S713.
    CrossRef
  67. Robert C, Schachter J, Long GV, et al. KEYNOTE-006 investigators. Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med. 2015; 372(26): 2521–2532.
    CrossRefPubMed
  68. Larkin J, Sileni VC, Marqueste CG, et al. LBA43 10-y survival outcomes from the phase III CheckMate 067 trial of nivolumab plus ipilimumab in advanced melanoma. Ann Oncol. 2024; 35: S1234–S1235.
    CrossRef

About cookies

Necessary cookies

Allways active

These cookies are necessary for the proper display and operation of the website. Blocking them may cause the website to malfunction.

Analytical cookies

As part of our website, we use analytical tools, such as Google Analytics, that allow us to verify website traffic. These tools may require the use of cookies.

Community cookies

These are cookies associated with the social networks we use. Accepting them will allow us to associate your visit to the site with our social media profiles.

Marketing cookies

These are cookies responsible for carrying out advertising and marketing activities - consenting to their use will allow us to target you with advertisements based on your previous activities within our website.

Copyright © 2023-2025 Via Medica Regulations Cookie policy Privacy Statement Legal Note